Rhythm Pharmaceuticals Net Worth
Rhythm Pharmaceuticals Net Worth Breakdown | RYTM |
Rhythm Pharmaceuticals Net Worth Analysis
Rhythm Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Rhythm Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Rhythm Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Rhythm Pharmaceuticals' net worth analysis. One common approach is to calculate Rhythm Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Rhythm Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Rhythm Pharmaceuticals' net worth. This approach calculates the present value of Rhythm Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Rhythm Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Rhythm Pharmaceuticals' net worth. This involves comparing Rhythm Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Rhythm Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Rhythm Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rhythm Pharmaceuticals' net worth research are outlined below:
| Rhythm Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 77.43 M. Net Loss for the year was (184.68 M) with profit before overhead, payroll, taxes, and interest of 99.72 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (136.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Rhythm Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 30771 shares by Pamela Cramer of Rhythm Pharmaceuticals at 19.02 subject to Rule 16b-3 |
Rhythm Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rhythm Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rhythm Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Rhythm Pharmaceuticals Target Price Consensus
Rhythm target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Rhythm Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Rhythm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Rhythm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Rhythm Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRhythm Pharmaceuticals Target Price Projection
Rhythm Pharmaceuticals' current and average target prices are 59.22 and 73.18, respectively. The current price of Rhythm Pharmaceuticals is the price at which Rhythm Pharmaceuticals is currently trading. On the other hand, Rhythm Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Rhythm Pharmaceuticals Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Rhythm Pharmaceuticals Target Price
Know Rhythm Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rhythm Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rhythm Pharmaceuticals backward and forwards among themselves. Rhythm Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rhythm Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Driehaus Capital Management Llc | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Rock Springs Capital Management Lp | 2024-09-30 | 1.2 M | Alkeon Capital Management, Llc | 2024-09-30 | 1.2 M | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 1.1 M | Checkpoint Capital Lp | 2024-09-30 | 663.4 K | Commodore Capital Lp | 2024-09-30 | 650 K | Loomis, Sayles & Company Lp | 2024-09-30 | 636.6 K | Hood River Capital Management Llc | 2024-09-30 | 614.6 K | Primecap Management Company | 2024-09-30 | 7.2 M | Blackrock Inc | 2024-09-30 | 6.9 M |
Follow Rhythm Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.51 B.Market Cap |
|
Project Rhythm Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.76) | (0.73) | |
| Return On Assets | (0.50) | (0.52) | |
| Return On Equity | (1.25) | (1.19) |
When accessing Rhythm Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Rhythm Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rhythm Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Rhythm Pharmaceuticals' management efficiency
Rhythm Pharmaceuticals has return on total asset (ROA) of (0.4624) % which means that it has lost $0.4624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.479) %, meaning that it created substantial loss on money invested by shareholders. Rhythm Pharmaceuticals' management efficiency ratios could be used to measure how well Rhythm Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2025, Return On Tangible Assets is likely to drop to -0.54. In addition to that, Return On Capital Employed is likely to grow to -0.73. At this time, Rhythm Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 30th of January 2025, Non Current Assets Total is likely to grow to about 29.6 M, while Total Current Assets are likely to drop about 178.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.65 | 2.97 | |
| Tangible Book Value Per Share | 2.54 | 2.94 | |
| Enterprise Value Over EBITDA | (13.85) | (14.54) | |
| Price Book Value Ratio | 14.06 | 14.76 | |
| Enterprise Value Multiple | (13.85) | (14.54) | |
| Price Fair Value | 14.06 | 14.76 | |
| Enterprise Value | 2.3 B | 2.4 B |
Understanding the operational decisions made by Rhythm Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 28.4103 | Revenue | Quarterly Revenue Growth 0.478 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rhythm Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rhythm Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rhythm Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rhythm Pharmaceuticals Corporate Filings
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 13th of November 2024 Other Reports | ViewVerify | |
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Rhythm Pharmaceuticals Earnings Estimation Breakdown
The calculation of Rhythm Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Rhythm Pharmaceuticals is estimated to be -1.016775 with the future projection ranging from a low of -1.155 to a high of -0.5475. Please be aware that this consensus of annual earnings estimates for Rhythm Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.16 Lowest | Expected EPS | -0.55 Highest |
Rhythm Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Rhythm Pharmaceuticals' value are higher than the current market price of the Rhythm Pharmaceuticals stock. In this case, investors may conclude that Rhythm Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Rhythm Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 11 | 93.06% | -0.73 | -1.016775 | -4.32 |
Rhythm Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Rhythm Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Rhythm Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Rhythm Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Rhythm Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Rhythm Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Rhythm Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Rhythm Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Rhythm Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -0.8 | -0.73 | 0.07 | 8 | ||
2024-08-06 | 2024-06-30 | -0.71 | -0.69 | 0.02 | 2 | ||
2024-05-07 | 2024-03-31 | -2.16 | -2.35 | -0.19 | 8 | ||
2024-02-22 | 2023-12-31 | -0.7 | -0.7 | 0.0 | 0 | ||
2023-11-07 | 2023-09-30 | -0.74 | -0.76 | -0.02 | 2 | ||
2023-08-01 | 2023-06-30 | -0.79 | -0.82 | -0.03 | 3 | ||
2023-05-02 | 2023-03-31 | -0.73 | -0.92 | -0.19 | 26 | ||
2023-03-01 | 2022-12-31 | -0.81 | -0.75 | 0.06 | 7 | ||
2022-11-08 | 2022-09-30 | -1 | -0.79 | 0.21 | 21 | ||
2022-08-02 | 2022-06-30 | -0.95 | -0.89 | 0.06 | 6 | ||
2022-05-03 | 2022-03-31 | -1.01 | -1.05 | -0.04 | 3 | ||
2022-03-01 | 2021-12-31 | -0.91 | -0.85 | 0.06 | 6 | ||
2021-11-02 | 2021-09-30 | -0.81 | -0.7 | 0.11 | 13 | ||
2021-08-03 | 2021-06-30 | -0.68 | -0.7 | -0.02 | 2 | ||
2021-05-03 | 2021-03-31 | 0.3 | -1.16 | -1.46 | 486 | ||
2021-03-01 | 2020-12-31 | -0.8 | -0.79 | 0.01 | 1 | ||
2020-11-02 | 2020-09-30 | -0.8 | -0.77 | 0.03 | 3 | ||
2020-08-03 | 2020-06-30 | -0.83 | -0.71 | 0.12 | 14 | ||
2020-05-04 | 2020-03-31 | -0.84 | -0.78 | 0.06 | 7 | ||
2020-03-02 | 2019-12-31 | -0.89 | -0.78 | 0.11 | 12 | ||
2019-11-01 | 2019-09-30 | -1.07 | -1.04 | 0.03 | 2 | ||
2019-07-29 | 2019-06-30 | -0.88 | -1.24 | -0.36 | 40 | ||
2019-05-03 | 2019-03-31 | -0.76 | -0.84 | -0.08 | 10 | ||
2019-03-08 | 2018-12-31 | -0.57 | -0.74 | -0.17 | 29 | ||
2018-11-09 | 2018-09-30 | -0.46 | -0.52 | -0.06 | 13 | ||
2018-08-08 | 2018-06-30 | -0.48 | -0.52 | -0.04 | 8 | ||
2018-05-14 | 2018-03-31 | -0.45 | -0.6 | -0.15 | 33 | ||
2018-03-12 | 2017-12-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2017-11-14 | 2017-09-30 | -0.4 | -1.51 | -1.11 | 277 | ||
2017-08-30 | 2017-06-30 | 0 | -0.41 | -0.41 | 0 | ||
2017-05-24 | 2017-03-31 | 0 | -0.29 | -0.29 | 0 |
Rhythm Pharmaceuticals Corporate Management
| Jennifer Lee | Executive America | Profile | |
| Yann Mazabraud | Executive International | Profile | |
| Christopher German | Principal Controller | Profile | |
| Sarah Ryan | Vice Marketing | Profile | |
| Jim Flaherty | Senior Counsel | Profile | |
| David Connolly | Head Communications | Profile | |
| Joseph Shulman | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share | Quarterly Revenue Growth 0.478 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.